Increased cell suspension concentration augments the survival rate of grafted tyrosine hydroxylase immunoreactive neurons

Journal of Neuroscience Methods

Volumn 166, Issue 1, 2007, Pages 13-19

  Terpstra, Brian T ^a   Collier, Timothy J ^a   Marchionini, Deanna M ^b   Levine, Nathan D ^a   Paumier, Katrina L ^a   Sortwell, Caryl E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Mesencephalon; Parkinson's disease; Survival; Transplant

Indexed keywords

TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SIZE; CELL SURVIVAL; CELL SUSPENSION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GRAFT SURVIVAL; HISTOCHEMISTRY; IMMUNOCOMPETENT CELL; MALE; MESENCEPHALON; NERVE FIBER TRANSECTION; NERVE GRAFT; NERVE TRANSECTION; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; STRIATE CORTEX; SURVIVAL RATE; TISSUE SECTION;

ANIMALS; BRAIN TISSUE TRANSPLANTATION; CELL COUNT; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CORPUS STRIATUM; DENERVATION; DOPAMINE; FETAL TISSUE TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, INBRED F344; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 34548486673     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2007.06.022     Document Type: Article

References (37)

1. Abercrombie M. Estimation of nuclear populations from mictrotome sections. Anat Rec 94 (1946) 239-247
2. Bergman H., and Deuschl G. Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Mov Disord 17 Suppl 3 (2002) S28-S40
3. Brundin P., Strecker R.E., Lindvall O., Isacson O., Nilsson O.G., Barbin G., et al. Intracerebral grafting of dopamine neurons. Experimental basis for clinical trials in patients with Parkinson's disease. Ann N Y Acad Sci 495 (1987) 473-496
4. Collier T.J., and Sortwell C.E. Therapeutic potential of nerve growth factors in Parkinson's disease. Drugs Aging 14 (1999) 261-287
5. Collier T.J., Sortwell C.E., and Daley B.F. Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation. J Neurosci 19 (1999) 5563-5573
6. Fawcett J.W., Barker R.A., and Dunnett S.B. Dopaminergic neuronal survival and the effects of bFGF in explant, three-dimensional and monolayer cultures of embryonic rat ventral mesencephalon. Exp Brain Res 106 (1995) 275-282
7. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (2001) 710-719
8. Fujita R., Yoshida A., Mizuno K., and Ueda H. Cell density-dependent death mode switch of cultured cortical neurons under serum-free starvation stress. Cell Mol Neurobiol 21 (2001) 317-324
9. Fukushima N., Ueda H., and Misu Y. Identification of novel endogenous factors against neuronal cell death in serum-free primary cultures. Soc Neurosci Abstr 20 (1994) 686
10. Gerhardt G.A., Yi C.W., Zhang A.Z., and Gash D.M. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem 80 (2002) 168-177
11. Giacobini M.M., Stromberg I., Almstrom S., Cao Y., and Olson L. Fibroblast growth factors enhance dopamine fiber formation from nigral grafts. Brain Res Dev Brain Res 75 (1993) 65-73
12. Granholm A.C., Mott J.L., Bowenkamp K., Eken S., Henry S., Hoffer B.J., et al. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum. Exp Brain Res 116 (1997) 29-38
13. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 62 (2004) S47-S55
14. Krobert K., Lopez-Colberg I., and Cunningham L.A. Astrocytes promote or impair the survival and function of embryonic ventral mesencephalon co-grafts: effects of astrocyte age and expression of recombinant brain-derived neurotrophic factor. Exp Neurol 145 (1997) 511-523
15. Liberto C.M., Albrecht P.J., Herx L.M., Yong V.W., and Levison S.W. Pro-regenerative properties of cytokine-activated astrocytes. J Neurochem 89 (2004) 1092-1100
16. Mahler M., Ferhat L., Gillian A., Ben-Ari Y., and Represa A. Tenascin-C mRNA and tenascin-C protein immunoreactivity increase in astrocytes after activation by bFGF. Cell Adhes Commun 4 (1996) 175-186
17. Marchionini D.M., Collier T.J., Camargo M., McGuire S., Pitzer M., and Sortwell C.E. Interference with anoikis-induced cell death of dopamine neurons: implications for augmenting embryonic graft survival in a rat model of Parkinson's disease. J Comp Neurol 464 (2003) 172-179
18. Marchionini D.M., Collier T.J., Pitzer M.R., and Sortwell C.E. Reassessment of caspase inhibition to augment grafted dopamine neuron survival. Cell Transplant 13 (2004) 273-282
19. Meiners S., Powell E.M., and Geller H.M. A distinct subset of tenascin/CS-6-PG-rich astrocytes restricts neuronal growth in vitro. J Neurosci 15 (1995) 8096-8108
20. Meredith J., Babak F., and Swartz M. The extracellular matrix as a cell survival factor. Mol Biol Cell 4 (1993) 953-961
21. Nikkhah G.O.P., Smits A., Tingstrom A., Othberg A., Brundin P., Funa K., et al. Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture. Exp Brain Res 92 (1993) 516-523
22. Nikkhah G., Olsson M., Eberhard J., Bentlage C., Cunningham M.G., and Bjorklund A. A microtransplantation approach for cell suspension grafting in the rat Parkinson model: a detailed account of the methodology. Neuroscience 63 (1994) 57-72
23. Olanow C.W., and Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22 (1999) 123-144
24. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (2003) 403-414
25. Raff M.C. Social controls on cell survival and cell death. Nature 356 (1992) 397-400
26. Rosenblad C., Martinez-Serrano A., and Bjorklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 75 (1996) 979-985
27. Sasaki Y., Fukushima N., Yoshida A., and Ueda H. Low density-induced apoptosis of cortical neurons is inhibited by serum factors. Cell Mol Neurobiol 18 (1998) 487-496
28. Sautter J., Sabel M., Sommer C., Strecker S., Weidner N., Oertel W.H., et al. BDNF and TrkB expression in intrastriatal ventral mesencephalic grafts in a rat model of Parkinson's disease. J Neural Transm 105 (1998) 253-263
29. Schaar D.G., Sieber B.A., Dreyfus C.F., and Black I.B. Regional and cell-specific expression of GDNF in rat brain. Exp Neurol 124 (1993) 368-371
30. Smits A., Odin P., Duan W.M., Brundin P., Widner H., Heldin C.H., et al. Expression of platelet-derived growth factor in and around intrastriatal embryonic mesencephalic grafts. Cell Transplant 2 (1993) 151-162
31. Sortwell C. Strategies for the augmentation of grafted dopamine neurons survival. Front Biosci 8 (2003) s522-s532
32. Sortwell C.E., Pitzer M.R., and Collier T.J. Time course of apoptotic cell death within mesencephalic cell suspension grafts: implications for improving grafted dopamine neuron survival. Exp Neurol 165 (2000) 268-277
33. Sullivan A.M., Pohl J., and Blunt S.B. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Eur J Neurosci 10 (1998) 3681-3688
34. Timmer M., Muller-Ostermeyer F., Kloth V., Winkler C., Grothe C., and Nikkhah G. Enhanced survival, reinnervation, and functional recovery of intrastriatal dopamine grafts co-transplanted with Schwann cells overexpressing high molecular weight FGF-2 isoforms. Exp Neurol 187 (2004) 118-136
35. Yurek D.M., and Seroogy K.B. Differential expression of neurotrophin and neurotrophin receptor mRNAs in and adjacent to fetal midbrain grafts implanted into the dopamine-denervated striatum. J Comp Neurol 423 (2000) 462-473
36. Yurek D.M., and Sladek Jr. J.R. Dopamine cell replacement: Parkinson's disease. Annu Rev Neurosci 13 (1990) 415-440
37. Yurek D.M., Lu W., Hipkens S., and Wiegand S.J. BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons. Exp Neurol 137 (1996) 105-118